Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | CTH | P32929 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221096 | 0.77 | HTT (0.42) | LMNAECE1KDM4EPLA2G2AACHE | |
| SCHEMBL25208944 | 0.76 | EGLN1 (0.42) | EGLN1CTHALDH1A1MAPTLMNA | |
| SCHEMBL1912605 | 0.76 | EGLN1 (0.63) | EGLN1ALDH1A1MAPTLMNAPTGS2 | |
| SCHEMBL15459770 | 0.74 | ACHE (0.52) | EGLN1ALDH1A1MAPTLMNAPTGS2 | |
| Hydrochloric Acid SCHEMBL27706409 | 0.74 | EGLN1 (0.61) | EGLN1ALDH1A1MAPTLMNAPTGS2 | |
| SCHEMBL2183329 | 0.74 | GAA (0.52) | ALDH1A1MAPTSMN1; SMN2KDM4EHTT | |
| SCHEMBL15190050 | 0.74 | EGLN1 (0.48) | EGLN1CTHALDH1A1MAPTLMNA | |
| SCHEMBL22830261 | 0.73 | EGLN1 (0.39) | EGLN1CTHALDH1A1MAPTLMNA | |
| SCHEMBL13153845 | 0.73 | ACHE (0.50) | EGLN1ACHE | |
| SCHEMBL16447317 | 0.73 | EGLN1 (0.39) | EGLN1ALDH1A1MAPTLMNAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521711-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | Alkermes, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011084849-A1 | DIARYLDIAZEPINE PRODRUGS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | SQLE, FDFT1, PTGIS | EGLN1 4033/4885CTH 365/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.